888720-26-1

Basic information

• Product Name: Pyrrolo[1,2-b]pyridazin-4...
• Synonyms: Pyrrolo[1,2-b]pyridazin-4...;Pyrrolo[1,2-b]pyridazin-4(1H)-one;1H,4H-pyrrolo[1,2-b]pyridazin-4-one;H-pyrrolo[1,2-b]pyridazin-4-ol;pyrrolo[1,2-b]pyridazin-4-ol;Pyrrolo[1,2-b]pyridazin-4(1H)
• CAS NO: 888720-26-1
• Molecular Formula: C₇H₆N₂O
• Molecular Weight: 134.13534
• Mol File: 888720-26-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 250.499°C at 760 mmHg
• Flash Point: 105.298°C
• Appearance: /
• Density: 1.331g/cm³
• Vapor Pressure: 0.022mmHg at 25°C
• Refractive Index: 1.668
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 4.23±0.30(Predicted)
• CAS DataBase Reference: Pyrrolo[1,2-b]pyridazin-4...(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrrolo[1,2-b]pyridazin-4...(888720-26-1)
• EPA Substance Registry System: Pyrrolo[1,2-b]pyridazin-4...(888720-26-1)

Safety Data

• Hazardous Substances Data: 888720-26-1(Hazardous Substances Data)

Usage

General Description

Pyrrolo[1,2-b]pyridazin-4-one is a heterocyclic compound with a pyrrolopyridazine core structure. It is a potential building block for pharmaceuticals and agrochemicals due to its diverse biological activities. The compound has shown anticancer, antiviral, and antifungal properties in experimental studies. It has also been investigated for its potential as a drug scaffold in the development of new therapeutic agents. The molecular structure of pyrrolo[1,2-b]pyridazin-4-one has been extensively studied using spectroscopic and computational methods to understand its chemical properties and potential applications in drug design and synthesis.

InChI:InChI=1/C7H6N2O/c10-7-3-4-8-9-5-1-2-6(7)9/h1-5,8H

Upstream product

• 156335-36-3 diethyl (1-pyrrolyl)aminomethylenepropanedioate 
• 156335-30-7 1,4-dihydro-4-oxopyrrolo<1,2-b>pyridazine-3-carboxylic acid 
• 156335-37-4 ethyl 1,4-dihydro-4-oxopyrrolo<1,2-b>pyridazine-3-carboxylate 

Downstream Products

• 1187875-95-1 4-(4-nitrophenoxy)-pyrrolo[1,2-b]pyridazine 
• 1221713-69-4 N-(4-(5-bromopyrrolo[1,2-b]pyridazin-4-yloxy)-3-fluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 888720-27-2 4-(2-fluoro-4-nitrophenoxy)pyrrolo[1,2-b]pyridazine 
• 1221714-44-8 5-bromo-4-(2-fluoro-4-nitrophenoxy)pyrrolo[1,2-b]pyridazine 
• 1221714-45-9 4-(5-bromopyrrolo[1,2-b]pyridazin-4-yloxy)-3-fluoroaniline 
• 1221714-55-1 1-(4-(2-fluoro-4-nitrophenoxy)pyrrolo[1,2-b]pyridazin-5-yl)ethanone 
• 1221713-71-8 N-(3-fluoro-4-(5-phenylpyrrolo[1,2-b]pyridazin-4-yloxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1187875-97-3 4-(pyrrolo[1,2-b]pyridazin-4-yloxy)benzenamine 

Relevant articles and documents

CONDENSED HETEROCYCLIC COMPOUND

Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].

AURORA KINASE MODULATORS AND METHOD OF USE

The present invention relates to chemical compounds having a general formula (I) wherein A1-5 and 7-8, D', L1, L2, R1, R3, R6-8, n and o are defined herein, and synthetic intermediates, which are capable of modulating the activity of Aurora kinase proteins and, thereby, influencing various disease states and conditions related to the activities of Aurora kinases. For example, the compounds are capable of influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.